Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
TR Lim Centre for Liver Research and NIHR Biomedical Research Unit in Liver Disease, University of Birmingham and Liver and Hepatobiliary Unit, Queen Elizabeth Hospital Birmingham, UK Abstract: Metabolic syndrome is prevalent in patients with hepatitis C virus (HCV) infection. Given the pandemic s...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-12-01
|
Series: | Hepatic Medicine : Evidence and Research |
Online Access: | http://www.dovepress.com/metabolic-syndrome-in-chronic-hepatitis-c-infection-does-it-still-matt-peer-reviewed-article-HMER |
id |
doaj-02779ece64b04fa19406d21e15f85d6b |
---|---|
record_format |
Article |
spelling |
doaj-02779ece64b04fa19406d21e15f85d6b2020-11-24T21:06:41ZengDove Medical PressHepatic Medicine : Evidence and Research1179-15352014-12-012014default11311819395Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?Lim TR TR Lim Centre for Liver Research and NIHR Biomedical Research Unit in Liver Disease, University of Birmingham and Liver and Hepatobiliary Unit, Queen Elizabeth Hospital Birmingham, UK Abstract: Metabolic syndrome is prevalent in patients with hepatitis C virus (HCV) infection. Given the pandemic spread of HCV infection and metabolic syndrome, the burden of their interaction is a major public health issue. The presence of metabolic syndrome accelerates the progression of liver disease in patients with HCV infection. New drug development in HCV has seen an unprecedented rise in the last year, which resulted in better efficacy, better tolerance, and a shorter treatment duration. This review describes the underlying mechanisms and clinical effects of metabolic syndrome in HCV infection, as well as their importance in the era of new directly acting antiviral therapy. Keywords: HCV, genotype 3, metabolic syndrome, steatosis, directly acting antiviral agentshttp://www.dovepress.com/metabolic-syndrome-in-chronic-hepatitis-c-infection-does-it-still-matt-peer-reviewed-article-HMER |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lim TR |
spellingShingle |
Lim TR Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? Hepatic Medicine : Evidence and Research |
author_facet |
Lim TR |
author_sort |
Lim TR |
title |
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? |
title_short |
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? |
title_full |
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? |
title_fullStr |
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? |
title_full_unstemmed |
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? |
title_sort |
metabolic syndrome in chronic hepatitis c infection: does it still matter in the era of directly acting antiviral therapy? |
publisher |
Dove Medical Press |
series |
Hepatic Medicine : Evidence and Research |
issn |
1179-1535 |
publishDate |
2014-12-01 |
description |
TR Lim Centre for Liver Research and NIHR Biomedical Research Unit in Liver Disease, University of Birmingham and Liver and Hepatobiliary Unit, Queen Elizabeth Hospital Birmingham, UK Abstract: Metabolic syndrome is prevalent in patients with hepatitis C virus (HCV) infection. Given the pandemic spread of HCV infection and metabolic syndrome, the burden of their interaction is a major public health issue. The presence of metabolic syndrome accelerates the progression of liver disease in patients with HCV infection. New drug development in HCV has seen an unprecedented rise in the last year, which resulted in better efficacy, better tolerance, and a shorter treatment duration. This review describes the underlying mechanisms and clinical effects of metabolic syndrome in HCV infection, as well as their importance in the era of new directly acting antiviral therapy. Keywords: HCV, genotype 3, metabolic syndrome, steatosis, directly acting antiviral agents |
url |
http://www.dovepress.com/metabolic-syndrome-in-chronic-hepatitis-c-infection-does-it-still-matt-peer-reviewed-article-HMER |
work_keys_str_mv |
AT limtr metabolicsyndromeinchronichepatitiscinfectiondoesitstillmatterintheeraofdirectlyactingantiviraltherapy |
_version_ |
1716765044521304064 |